Genzyme pursues Renagel reimbursement
Executive Summary
Sen. Kerry (D-Mass.) introduces legislation (S 1304) Aug. 2 to provide coverage under Medicare for phosphate binding drugs for dialysis patients with end-stage renal disease. Genzyme's Renagel and Braintree's PhosLo would be covered under the proposed legislation. Both companies are based in Massachusetts